Who we are

Fundació ACE – Barcelona Alzheimer’s Treatment & Research Center and the Alzheimer’s disease Research Center (ADRC) of the University Of Pittsburgh School Of Medicine organize since 1998 the biennial Barcelona–Pittsburgh Conference.

What we do

We work to offer a quality conference bringing together panelists of recognized national and international scientific prestige; and creating an interactive space related to neuroscience, with the ultimate objective of benefiting the affected people and their families.

Why us?

Over the years, the Barcelona – Pittsburgh Conference has become a reference in the field of dementia. The conference is aimed at all professionals working with dementia, both from a medical and a socio-legal perspective.

Speakers

Speakers area

  • Mercè Boada

    CMO. Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Universitat Internacional de Catalunya, Spain

  • Oscar López

    University of Pittsburgh, Scientific Committee of Fundació ACE

  • Victor Villemagne

    Associate Professor of Medicine, The University of Melbourne. Deputy Director, Molecular Imaging Research, Austin Health. Melbourne, Australia.

  • James T. Becker

    University of Pittsburgh. Scientific Committee of Fundació ACE

  • Marta Marquié

    Fundació ACE - Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain.

  • Carla Abdelnour

    Fundació ACE - Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain.

  • Agustín Ruiz

    CSO. Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Universitat Internacional de Catalunya, Spain

  • Adela Orellana

    Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Universitat Internacional de Catalunya, Spain

  • Montserrat Alegret

    Head of Neuropsychology. Research Center and Memory Clinic. Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona – Universitat Internacional de Catalunya, Barcelona, Spain.

  • Isabel Hernández

    Fundació ACE, Barcelona

  • Lluís Tárraga

    CEO. Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Universitat Internacional de Catalunya, Spain

  • Gemma Monté

    Head of Neuroimaging. Research Center and Memory Clinic. Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona – Universitat Internacional de Catalunya, Barcelona, Spain.

  • Silvia Gil

    Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Universitat Internacional de Catalunya, Spain

  • Ayda Rostamzadeh

    Attending physician at the Department of Psychiatry and Psychotherapy, University Hospital of Cologne. Cologne, Germany

Program

View full program
Day 1
23 May 2018
Day 2
24 May 2018
Day 3
25 May 2018
08:00 - 14:00

II Symposium on Dementia Genetics

14:00 - 15:30

Registration | World Trade Center

15:30-15:40
Welcome and objectives | WORKSHOP ON ETHICS

Welcome and objectives | WORKSHOP ON ETHICS

By: Mercè Boada, Fundació ACE, Barcelona, Frank Jessen, University of Cologne. PreDADQoL Study.
15:40 - 16:35

Panel: Predictive Diagnosis of Alzheimer’s disease: Quality of Life of Individuals at Risk and their Close Other (PreDADQoL).

15:41 - 16:05
Ethics and Alzheimer’s: what is changing.

Ethics and Alzheimer’s: what is changing.

Núria Terribas, Director of Fundació Víctor Grifols i Lucas.
16:05 - 16:20
Ayda Rostamzadeh

Effects of biomarker-based dementia risk disclosure in patients with MCI – Design of the clinical subproject in the PreDADQoL study.

Ayda Rostamzadeh
16:20 - 16:35
Expectations of MCI patients and their caregivers towards biomarker-based predictive AD diagnosis – Preliminary findings from the PreDADQoL study.

Expectations of MCI patients and their caregivers towards biomarker-based predictive AD diagnosis – Preliminary findings from the PreDADQoL study.

16:30 - 17:35

Panel: How to manage disclosures using biomarkers?

16:35 – 16.55
Cerebrospinal fluid (CSF) biomarkers.

Cerebrospinal fluid (CSF) biomarkers.

16:55 - 17:15
Positron emission tomography (PET) imaging.

Positron emission tomography (PET) imaging.

17:15 - 17:35
Disclosure of APOE Genotype and Risk of Alzheimer’s disease.

Disclosure of APOE Genotype and Risk of Alzheimer’s disease.

17:35 - 17:50

Coffee Break

17:50 - 18:30
DISCUSSION
Silvia Gil
Ayda Rostamzadeh
DISCUSSION
DISCUSSION
DISCUSSION
DISCUSSION
Mercè Boada
DISCUSSION

DISCUSSION

Chair: Björn Schmitz-Luhn, PreDADQoL project, University of Cologne
Silvia Gil
Ayda Rostamzadeh
Mercè Boada
07:30 - 08:30

Registration

08:30 - 09:00
Hot topic lecture | Challenges and Progress in Imaging Proteinopathies.

Hot topic lecture | Challenges and Progress in Imaging Proteinopathies.

Chair: Gemma Monté, Fundació ACE, Barcelona
09:00 - 10:00

Panel | Neuroimaging

9:01 - 9:20
Perplexes of current Tau PET imaging: importance of neuropathology validation.

Perplexes of current Tau PET imaging: importance of neuropathology validation.

9:20 - 9:40
Analysis of anatomical MRI using SPM.

Analysis of anatomical MRI using SPM.

9:40 - 10:00
Two-year longitudinal monitoring of amnestic mild cognitive impairment patients with prodromal Alzheimer’s disease using topographical biomarkers derived from resting state fMRI.

Two-year longitudinal monitoring of amnestic mild cognitive impairment patients with prodromal Alzheimer’s disease using topographical biomarkers derived from resting state fMRI.

10:00 - 10:15

Coffee Break

10:15 - 10:45
Victor Villemagne

Hot topic lecture | Use of amyloid imaging in clinical trials and for the validation of fluid Biomarkers.

Chair: Pedro Pesini, Araclon.
Victor Villemagne
10:45 - 11:45

Panel | Biomarkers

10:46 - 11:05
Albumin functionality in Alzheimer Disease.

Albumin functionality in Alzheimer Disease.

11:05 - 11:25
Omics approximation in the study of CSF in AD patients.

Omics approximation in the study of CSF in AD patients.

11:25 - 11:45
Novel Insights into the Functional Plasma Proteome in Alzheimer’s disease.

Novel Insights into the Functional Plasma Proteome in Alzheimer’s disease.

11:45 - 12:45

Official Opening | 5th “Fundació ACE. Joan Boada & Mercè Rovira” award

12:45 - 13:15
James T. Becker

Hot topic lecture | Explorations in the aging human connectome.

Chair: Lluís Tárraga, Fundació ACE, Barcelona
James T. Becker
13:45 - 14:45

Lunch

15:00 - 15:30
Hot topic lecture | Epigenomics of Dementia.

Hot topic lecture | Epigenomics of Dementia.

Chair: Agustín Ruiz, Fundació ACE, Barcelona
15:30 - 16:30

Panel | Advances in genomics.

15:31 - 15:50
How Can we Accelerate Dementia Prevention and Treatment? Population Neuroscience and Personalized Care.

How Can we Accelerate Dementia Prevention and Treatment? Population Neuroscience and Personalized Care.

15:50 - 16:10
Exploring biological consequences of genetic risk factors for Alzheimer’s disease.

Exploring biological consequences of genetic risk factors for Alzheimer’s disease.

16:10 - 16:30
Genetic risk for schizophrenia and psychosis in Alzheimer disease.

Genetic risk for schizophrenia and psychosis in Alzheimer disease.

16:30 - 17:00
Hot topic lecture | Innovative strategies in AD

Hot topic lecture | Innovative strategies in AD

Chair: Mercè Boada, Fundació ACE, Barcelona
17:00 - 18:00

Panel | Innovative strategies 1

17:01 - 17:15
Update on the clinical development of ABvac40, an active immunotherapy against Alzheimer’s disease.

Update on the clinical development of ABvac40, an active immunotherapy against Alzheimer’s disease.

17:15 - 17:30
Plasma Exchange in AD.

Plasma Exchange in AD.

17:30 - 17:45
Aducanumab 36-Month Data from the PRIME Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients with Prodromal or Mild Alzheimer’s disease.

Aducanumab 36-Month Data from the PRIME Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients with Prodromal or Mild Alzheimer’s disease.

17:45 - 18:00
Lilly BACE Inhibitor Program and Early Phase Pipeline.

Lilly BACE Inhibitor Program and Early Phase Pipeline.

18:00 - 18:15

Coffee break

18:15 - 19:00

Panel | Innovative strategies 2

18:16 - 18:30
Disease modifying combination therapy in next generation clinical trials.

Disease modifying combination therapy in next generation clinical trials.

18:30 - 18:45
Roche in Alzheimer’s disease – Current developments.

Roche in Alzheimer’s disease – Current developments.

18:45 - 19:00
AbbVie’s vision for interventions in Alzheimer’s Disease.

AbbVie’s vision for interventions in Alzheimer’s Disease.

19:00 - 19:30
Hot topic lecture | Present and future of CSF biomarkers.

Hot topic lecture | Present and future of CSF biomarkers.

Chair: Adela Orellana, Fundació ACE, Barcelona.
08:30 - 09:00
Oscar López

Hot topic lecture | The long term prediction of incident dementia by commonly used biomarkers: amyloid deposition, neurodegeneration and vascular disease.

Chair: Isabel Hernández, Fundació ACE, Barcelona
Oscar López
09:00 - 10:00

Panel | Spanish cohorts

09:01 - 09:15
Gemma Monté

FACEHBI: Fundació ACE Healthy Brain Initiative.

Gemma Monté
09:15 - 09:30
The Vallecas Project: Predicting future development of mild cognitive impairment in the cognitively healthy elderly.

The Vallecas Project: Predicting future development of mild cognitive impairment in the cognitively healthy elderly.

09:30 - 09:45
Proyecto Gipuzkoa Alzheimer; estudio Deba; programa GOIZ-Beasain.

Proyecto Gipuzkoa Alzheimer; estudio Deba; programa GOIZ-Beasain.

9:45 - 10:00
The ALFA Study. First results in a middle-aged cognitively healthy cohort.

The ALFA Study. First results in a middle-aged cognitively healthy cohort.

10:00 - 10:30
Hot topic lecture | Subjective Cognitive Decline: a new scope

Hot topic lecture | Subjective Cognitive Decline: a new scope

Chair: Octavio Rodríguez, Fundació ACE, Barcelona.
10:30 - 11:00

Coffee Break

11:00 - 12:00

Panel | Prediction and prevention

11:01 - 11:20
Models of Patient Engagement for Alzheimer’s Disease (MOPEAD): estrategias para el diagnóstico precoz en la comunidad.

Models of Patient Engagement for Alzheimer’s Disease (MOPEAD): estrategias para el diagnóstico precoz en la comunidad.

11:15 - 11:30
Does the prevalence of MCI decline? Evidence from a prospective, population-based longitudinal study with a follow-up of 25 years.

Does the prevalence of MCI decline? Evidence from a prospective, population-based longitudinal study with a follow-up of 25 years.

11:30 - 11:45
Using PET imaging to study Alzheimer’s disease pathology: A Role for Lifestyle?

Using PET imaging to study Alzheimer’s disease pathology: A Role for Lifestyle?

11:45 - 12:00
Sustaining Brain Health and Promoting Resilience to Prevent Dementia.

Sustaining Brain Health and Promoting Resilience to Prevent Dementia.

12:00 - 12:30
Hot topic lecture | Presymptomatic brain changes in familial Alzheimer’s disease: implications for prevention trials

Hot topic lecture | Presymptomatic brain changes in familial Alzheimer’s disease: implications for prevention trials

Chair: Marcelo Berthier, Universidad de Málaga.
12:30 - 13:30

Panel | New approaches on neuropsychology

12:30 - 12:40
Cambios cerebrales adaptativos o compensatorios en la organización del lenguaje en el envejecimiento.

Cambios cerebrales adaptativos o compensatorios en la organización del lenguaje en el envejecimiento.

12:40 - 12:50
Montserrat Alegret

The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to brain amyloid burden in Subjective Cognitive Decline

Montserrat Alegret
12:50 - 13:00
Accelerated long-term forgetting in asymptomatic individuals at risk of familial and sporadic Alzheimer’s disease.

Accelerated long-term forgetting in asymptomatic individuals at risk of familial and sporadic Alzheimer’s disease.

13:00 - 13:30
Final remarks and future scope
James T. Becker
Final remarks and future scope
Oscar López

Final remarks and future scope

Chairs: Mercè Boada Fundació ACE, Barcelona, Agustín Ruiz Fundació ACE, Barcelona
James T. Becker
Oscar López
13:30 - 13:45
Closing Ceremony
Lluís Tárraga

Closing Ceremony

Lluís Tárraga
 
 
 

Location

World Trade Center
Edif. Este, Moll de Barcelona, s/n, 08039 Barcelona
+34 935 08 80 00bcnpit@fundacioace.org

Register online

Sponsors

Register online

Select your event

If you are a member of the Societat Catalana de Neurologia (SCN), Ciberned, EAIA or you can have some discount for the Conference, please contact bcnpit@fundacioace.org

All Barcelona – Pittsburgh attendees can benefit from discounted hotel room rates at the Tryp Barcelona Apolo hotel. You can ask our agency to book a room for you via secretaria@suportserveis.com or calling at + 34 93 201 75 71.